Dr. Paul Marks joins Cellceutix SAB

Dr. Paul Marks, who served as CEO of Memorial Sloan-Kettering Cancer Center from 1980 to 1999, has joined the Scientific Advisory Board of Cellceutix (OTCBB:CTIX) . He remains president emeritus and a member of the Sloan-Kettering Institute.

Dr. Marks’ research in cell biology and cancer genetics has made major contributions toward a new approach to cancer treatment and prevention, through the development of new and more potent chemotherapy and chemoprevention agents.

“We have assembled a world-class advisory board with Dr. Emil Frei, Dr. Samuel Danishefsky, Dr. Paul Ginsburg and now Dr. Paul Marks,” Cellceutix CSO Dr. Krishna Menon said in a statement. “Going forward with Kevetrin in clinical trials, as well as other drugs in our pipeline, their experience and knowledge will play a key role in our success.”

Cellceutix also said it has filed foreign patent applications relating to pharmaceutical compositions comprising its anti-cancer compound Kevetrin. These applications are based on the earlier international application filed under the Patent Cooperation Treaty in 2009.